Compass Therapeutics (CMPX) Research & Development (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Research & Development for 3 consecutive years, with $13.7 million as the latest value for Q4 2025.
- Quarterly Research & Development rose 4.86% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.0 million through Dec 2025, up 32.17% year-over-year, with the annual reading at $56.0 million for FY2025, 32.18% up from the prior year.
- Research & Development hit $13.7 million in Q4 2025 for Compass Therapeutics, up from $12.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $16.4 million in Q2 2025 to a low of $6.6 million in Q1 2023.
- Historically, Research & Development has averaged $11.4 million across 3 years, with a median of $11.8 million in 2023.
- Biggest five-year swings in Research & Development: fell 2.48% in 2024 and later soared 48.93% in 2025.
- Year by year, Research & Development stood at $12.4 million in 2023, then rose by 4.93% to $13.0 million in 2024, then rose by 4.86% to $13.7 million in 2025.
- Business Quant data shows Research & Development for CMPX at $13.7 million in Q4 2025, $12.8 million in Q3 2025, and $16.4 million in Q2 2025.